Formation and improvement of surgery-based treatment system for gastric cancer

doi:10.16139/j.1007-9610.2023.01.04

Abstract

Abstract:

The treatment of gastric cancer is based on surgical resction. The accumulation of clinical research and in-depth understanding of tumor constitute the cornerstone of gastric cancer treatment. Development of surgical technique and many approaches of treatment including laparoscopic technique and neoadjuvant therapy compensate the boundedness of simply surgery. This study summarized ①both theoretical and technological progress in surgery; ②combined with the current study situation of perioperative treatment; ③systematically expounded the formation and improvement of surgery-based treatment system for gastric cancer management.

Key words: Gastric cancer, Surgical treatment, Perioperative treatment

CLC Number:

R735.2

ZHAO Fazhi, ZHAO Ping. Formation and improvement of surgery-based treatment system for gastric cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 24-30.

References 39

[1]	中华人民共和国国家卫生健康委员会医政医管局. 胃癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(9):1137-1164.
	Bureau of Medical Administration. National Health Commission of the People′s Republic of China. Standardization for diagnosis and treatment of gastric cancer (2022 edition)[J]. Chin J Dig Surg, 2022, 21(9):1137-1164.
[2]	中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会胃癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2022, 102(16):1169-1189.
	Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Chinese Medical Association guidelines for clinical diagnosis and treatment of gastric cancer (edition 2021)[J]. Chin J Med, 2022, 102(16):1169-1189.
[3]	朱正纲. 编者的话[J]. 中国癌症杂志, 2022, 32(7):前插1.
	ZHU Z G. Editor’s talk[J]. China Oncol, 2022, 32(7):1.
[4]	FUJITANI K, YANG H K, MIZUSAWA J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7 URL
[5]	聂明明, 朱正纲. 腹腔镜探查对进展期胃癌精准分期的临床意义[J]. 外科理论与实践, 2022, 27(4):365-369.
	NIE M M, ZHU Z G. Clinical significance of diagnostic laparoscopy on precision staging in advanced gastric cancer[J]. J Surg Concepts Pract, 2022, 27(4):365-369.
[6]	AJANI J A, D'AMICO T A, BENTREM D J, et al. Gastric Cancer, Version 2, 2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192. doi: 10.6004/jnccn.2022.0008 URL
[7]	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition)[J]. Gastric Cancer, 2023, 26(1):1-25. doi: 10.1007/s10120-022-01331-8
[8]	ZHU B Y, YUAN S Q, NIE R C, et al. Prognostic factors and recurrence patterns in T4 gastric cancer patients after curative resection[J]. J Cancer, 2019, 10(5):1181-1188. doi: 10.7150/jca.28993 URL
[9]	AVERSA J G, DIGGS L P, HAGERTY B L, et al. Multivisceral resection for locally advanced gastric cancer[J]. J Gastrointest Surg, 2021, 25(3):609-622. doi: 10.1007/s11605-020-04719-y
[10]	CHANG S C, TANG C M, LE P H, et al. Impact of pancreatic resection on survival in locally advanced resectable gastric cancer[J]. Cancers (Basel), 2021, 13(6):1289. doi: 10.3390/cancers13061289 URL
[11]	ENDO S, IKENAGA M, YAMADA T, et al. Prognostic factors for para-aortic lymph node dissection after neoadjuvant chemotherapy for gastric cancer[J]. Anticancer Res, 2020, 40(4):2351-2357. doi: 10.21873/anticanres.14203 pmid: 32234937
[12]	XU Z Y, HU C, CHEN S, et al. Evaluation of D2-plus radical resection for gastric cancer with pyloric invasion[J]. BMC Surg, 2019, 19(1):172. doi: 10.1186/s12893-019-0605-6
[13]	LIANG Y, CUI J, CAI Y, et al. “D2 plus” lymphadenectomy is associated with improved survival in distal gastric cancer with clinical serosa invasion: a propensity score analysis[J]. Sci Rep, 2019, 9(1):19186. doi: 10.1038/s41598-019-55535-7
[14]	马君俊, 臧潞. 积跬步以至千里——致敬中国腹腔镜胃癌外科[J]. 中华胃肠外科杂志, 2022, 25(8):686-693.
	MA J J, ZANG L. Small steps to thousands of miles: a tribute to Chinese laparoscopic gastric cancer surgery[J]. Chin J Gastrointest Surg, 2022, 25(8):686-693.
[15]	陈凛, 李少卿, 张珂诚. 中国腹腔镜胃癌手术20年回顾与展望[J]. 中华普外科手术学杂志(电子版), 2021, 15(2):119-122.
	CHEN L, LI S Q, ZHANG K C. Review and prospect of laparoscopic surgery for gastric cancer in China in the past 20 years[J]. Chin J Oper Proc Gen Surg(Electronic Edition), 2021, 15(2):119-122.
[16]	QUAN Y, HUANG A, YE M, et al. Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis[J]. Gastric Cancer, 2016, 19(3):939-950. doi: 10.1007/s10120-015-0516-x URL
[17]	PARK S H, KIM A, KWON Y, 等. 腹腔镜胃癌手术的历史与展望[J]. 中华消化外科杂志, 2020, 19(5):496-504.
	PARK S H, KIM A, KWON Y, et al. The history and prospect of laparoscopic gastric cancer surgery[J]. Chin J Dig Surg, 2020, 19(5):496-504.
[18]	SON S Y, HUR H, HYUNG W J, et al. Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer: 5-year outcomes of the KLASS-02 randomized clinical trial[J]. JAMA Surg, 2022, 157(10):879-886. doi: 10.1001/jamasurg.2022.2749 URL
[19]	WONG J. Effect of laparoscopic vs. open distal gastrectomy on 3-year disease free survival in patients with locally advanced gastric cancer: commentary on the CLASS-01 randomized clinical trial[J]. Transl Gastroenterol Hepatol, 2019, 4:78. doi: 10.21037/tgh URL
[20]	YU J, HUANG C, SUN Y, et al. Effect of laparoscopic vs.open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20):1983-1992. doi: 10.1001/jama.2019.5359 URL
[21]	国际食管疾病学会中国分会CSDE食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018年版)[J]. 中华胃肠外科杂志, 2018, 21(9):961-975.
	Multidisciplinary Union for Esophagogastric Junction Diseases of Chinese Society for Diseases of the Esophagus CSDE, Laparoscopic Surgery Committee of the Endoscopist Branch in the Chinese Medical Doctor Association CMDA, Upper Digestive Tract Surgeons Committee of the Surgeon Branch in the Chinese Medical Doctor Association CMDA, et al. Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction (2018 edition)[J]. Chin J Gastrointest Surg, 2018, 21(9):961-975.
[22]	中华医学会外科学分会腹腔镜与内镜外科学组. SiewertⅡ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(11):1129-1135. doi: 10.19538/j.cjps.issn1005-2208.2019.11.02
	Chinese Society of Laparoscopic and Endoscopic Surgery, Chinese Surgical Society, Chinese Medical Association. Chinese expert consensus on laparoscopy surgry for SiewertⅡ adenocarcinoma of esophagogastric junction(2019 edition)[J]. Chin J Pract Surg, 2019, 39(11):1129-1135.
[23]	赵骏杰, 刘凤林. 食管胃结合部腺癌腹腔镜近端胃切除术及淋巴结清扫[J]. 中华胃肠外科杂志, 2022, 25(2):114-119.
	ZHAO J J, LIU F L. Laparoscopic proximal gastrectomy and lymph node resection in adenocarcinoma of the esophagogastric junction[J]. Chin J Gastrointest Surg, 2022, 25(2):114-119.
[24]	李双喜, 李子禹. 食管胃结合部腺癌腹腔镜手术的下纵隔淋巴结清扫边界及质量控制[J]. 中华胃肠外科杂志, 2022, 25(2):120-123.
	LI S X, LI Z Y. Dissection borders of laparoscopic lower mediastinal lymphadenectomy for adenocarcinoma of esophagogastric junction and the quality control[J]. Chin J Gastrointest Surg, 2022, 25(2):120-123.
[25]	TRAPANI R, RAUSEI S, REDDAVID R, et al. Risk factors for esophago-jejunal anastomosis leakage after total gastrectomy for cancer. A multicenter retrospective study of the Italian research group for gastric cancer[J]. Eur J Surg Oncol, 2020, 46(12):2243-2247. doi: 10.1016/j.ejso.2020.06.035 pmid: 32703713
[26]	SAKAMOTO T, FUJIOGI M, MATSUI H, et al. Short-term outcomes of laparoscopic and open total gastrectomy for gastric cancer: a nationwide retrospective cohort analysis[J]. Ann Surg Oncol, 2020, 27(2):518-526. doi: 10.1245/s10434-019-07688-y pmid: 31407172
[27]	SUGITA H, SAKURAMOTO S, OYA S, et al. Linear stapler anastomosis for esophagogastrostomy in laparoscopic proximal gastrectomy reduce reflux esophagitis[J]. Langenbecks Arch Surg, 2021, 406(8):2709-2716. doi: 10.1007/s00423-021-02250-5
[28]	KURODA S, CHODA Y, OTSUKA S, et al. Multicenter retrospective study to evaluate the efficacy and safety of the double-flap technique as antireflux esophagogastrostomy after proximal gastrectomy (rD-FLAP Study)[J]. Ann Gastroenterol Surg, 2018, 3(1):96-103. doi: 10.1002/ags3.2019.3.issue-1 URL
[29]	XIAO S M, ZHAO P, DING Z, et al. Laparoscopic proximal gastrectomy with double-tract reconstruction for upper third gastric cancer[J]. BMC Surg, 2021, 21(1):140. doi: 10.1186/s12893-021-01153-y
[30]	KANAJI S, YAMAZAKI Y, KUDO T, et al. Comparison of laparoscopic gastrectomy with 3-D/HD and 2-D/4 K camera system for gastric cancer: a prospective randomized control study[J]. Langenbecks Arch Surg, 2022, 407(1):105-112. doi: 10.1007/s00423-021-02302-w
[31]	ZHANG L, HONG H, ZANG L, et al. Application value of 4K high-definition system in laparoscopic gastrectomy: preliminary results and initial experience[J]. J Laparoendosc Adv Surg Tech A, 2022, 32(2):137-141. doi: 10.1089/lap.2020.0931 URL
[32]	张晓倩, 张旺, 宋云林. 机器人与腹腔镜胃癌根治术疗效的Meta分析[J]. 腹腔镜外科杂志, 2022, 27(2):96-102.
	ZHANG X Q, ZHANG W, SONG Y L. Meta-analysis of the efficacy of robot-assisted and laparoscopic radical gastrectomy for gastric cancer[J]. J Laparoscopic Surg, 2022, 27(2):96-102.
[33]	BARAL S, ARAWKER M H, SUN Q, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: a mega meta-analysis[J]. Front Surg, 2022, 9:895976. doi: 10.3389/fsurg.2022.895976 URL
[34]	NISHI M, SHIMADA M, YOSHIKAWA K, et al. Propensity score-matched analysis of the short- and long-term outcomes of robotic versus laparoscopic gastrectomy for gastric cancer[J]. Ann Surg Oncol, 2022, 29(6):3887-3895. doi: 10.1245/s10434-021-11203-7
[35]	陆晓峰, 刘颂, 艾世超, 等. 纳米碳与吲哚菁绿导航腹腔镜胃癌根治术淋巴结清扫的对比性研究[J]. 中华普外科手术学杂志(电子版), 2021, 15(2):146-149.
	LU X F, LIU S, AI S C, et al. Comparative study of carbon nanoparticles and indocyanine green-guided lympha-denectomy during laparoscopic radical gastrectomy[J]. Chin J Oper Proc Gen Surg(Electronic Edition), 2021, 15(2):146-149.
[36]	ZHANG X, LIANG H, LI Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8):1081-1092. doi: 10.1016/S1470-2045(21)00297-7 URL
[37]	GUO H, DING P, SUN C, et al. Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: a single-arm, open-label, phase Ⅱ trial[J]. Front Oncol, 2022, 12:927781. doi: 10.3389/fonc.2022.927781 URL
[38]	BANG Y J, VAN CUTSEM E, FUCHS C S, et al. KEYNOTE-585: phase Ⅲ study of perioperative chemotherapy with or without pembrolizumab for gastric cancer[J]. Future Oncol, 2019, 15(9):943-952. doi: 10.2217/fon-2018-0581 URL
[39]	ANDRÉ T, TOUGERON D, PIESSEN G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase Ⅱ study[J]. J Clin Oncol, 2023, 41(2):255-265.